In addition, PPARγ agonists were associated with the development of hepatic steatosis in rodents [17], whereas several PPARγ antagonists were shown to ameliorate insulin resistance and hepatic steatosis, accompanied by reduced body weights [18, 19]. The gene discussed is PPARG; the disease is fatty liver disease.